urlscan.io logo urlscan.io
SecurityTrails logo

www.fiercebiotech.com Open in urlscan Pro
104.18.0.205  Public Scan

Back to summary
URL: https://www.fiercebiotech.com/biotech/novo-nordisk-doubles-down-valo-betting-190-million-near-term-apply-ai-obesity-and-diabetes
Submission: On January 08 via api from US — Scanned from PL

Form analysis 2 forms found in the DOM

GET /search-results

<form action="/search-results" method="get">
  <fieldset class="d-flex align-items-center position-relative input-search">
    <input type="text" placeholder="Search" name="fulltext_search" class="search-text w-100">
    <button class="search-submit d-flex align-items-center" id="header-search-submit" type="submit" aria-label="search">
      <svg aria-hidden="true" focusable="false" data-prefix="far" data-icon="search" class="svg-inline--fa fa-search fa-w-16" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512">
        <path fill="currentColor"
          d="M508.5 468.9L387.1 347.5c-2.3-2.3-5.3-3.5-8.5-3.5h-13.2c31.5-36.5 50.6-84 50.6-136C416 93.1 322.9 0 208 0S0 93.1 0 208s93.1 208 208 208c52 0 99.5-19.1 136-50.6v13.2c0 3.2 1.3 6.2 3.5 8.5l121.4 121.4c4.7 4.7 12.3 4.7 17 0l22.6-22.6c4.7-4.7 4.7-12.3 0-17zM208 368c-88.4 0-160-71.6-160-160S119.6 48 208 48s160 71.6 160 160-71.6 160-160 160z">
        </path>
      </svg>
    </button>
    <input type="hidden" placeholder="Search" name="dns" value="fiercehealthcare_com,fiercebiotech_com,fiercepharma_com">
  </fieldset>
</form>

GET /search-results

<form class="w-100" action="/search-results" method="get">
  <fieldset class="d-flex justify-content-between position-relative input-search">
    <input type="text" placeholder="Search" name="fulltext_search" class="search-text w-100">
    <button class="search-submit d-flex align-items-center" id="search-submit" type="submit" aria-label="search">
      <svg aria-hidden="true" focusable="false" data-prefix="far" data-icon="search" class="svg-inline--fa fa-search fa-w-16" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512">
        <path fill="currentColor"
          d="M508.5 468.9L387.1 347.5c-2.3-2.3-5.3-3.5-8.5-3.5h-13.2c31.5-36.5 50.6-84 50.6-136C416 93.1 322.9 0 208 0S0 93.1 0 208s93.1 208 208 208c52 0 99.5-19.1 136-50.6v13.2c0 3.2 1.3 6.2 3.5 8.5l121.4 121.4c4.7 4.7 12.3 4.7 17 0l22.6-22.6c4.7-4.7 4.7-12.3 0-17zM208 368c-88.4 0-160-71.6-160-160S119.6 48 208 48s160 71.6 160 160-71.6 160-160 160z">
        </path>
      </svg>
    </button>
  </fieldset>
</form>

Text Content

YOUR PRIVACY

Welcome! In order to deliver a personalized and enhanced site navigation, we
store information on how you use the site. We want you to know that we respect
your privacy and your right to control how we collect and use your personal
data. For more information, please see the Questex Privacy Policy



Manage my cookie preferences


Reject AllAccept All

 * Fierce Pharma
 * Fierce Biotech
 * Fierce Healthcare
 * Fierce Life Sciences Events

 * Advertise
 * About Us



 * Biotech
   
   * Cell & Gene Therapy
   * Clinical Data
   * Venture Capital
   * Deals
 * Research
 * Medtech
   
   * Devices
   * Diagnostics
   * AI and Machine Learning
 * CRO
 * Special Reports
 * Trending Topics
   
   * Clinical Development
   * Biologics
 * Fierce 50
   
   * Special Report
   * Awards Gala

 * Resources
   
   * Fierce Events
   * Industry Events
   * Webinars
   * Podcasts
   * Whitepapers
   * Survey
 * Events
   
   
 * Subscribe

Trending T

 * Biotech
   
   * Cell & Gene Therapy
   * Clinical Data
   * Venture Capital
   * Deals
 * Research
 * Medtech
   
   * Devices
   * Diagnostics
   * AI and Machine Learning
 * CRO
 * Special Reports
 * Trending Topics
   
   * Clinical Development
   * Biologics
 * Fierce 50
   
   * Special Report
   * Awards Gala

 * Resources
   
   * Fierce Events
   * Industry Events
   * Webinars
   * Podcasts
   * Whitepapers
   * Survey
 * Events
   
   
 * Subscribe

 * Fierce Pharma
 * Fierce Biotech
 * Fierce Healthcare
 * Fierce Life Sciences Events

 * Advertise
 * About Us




Biotech


NOVO NORDISK DOUBLES DOWN ON VALO, BETTING $190M NEAR-TERM TO APPLY AI TO
OBESITY AND DIABETES

By Nick Paul Taylor Jan 8, 2025 8:00am
Novo Nordisk Valo Health Artificial Intelligence obesity drugs


Novo Nordisk is doubling down on its collaboration with Valo Health, committing
up to $190 million in near-term payments—and billions on the back end—to apply
artificial intelligence to up to 20 programs.

The Danish drugmaker began working with Valo, a Flagship Pioneering company with
big ambitions for AI, in 2023. That deal was worth $60 million upfront, gave
Novo three cardiovascular assets and set the stage for work on up to 11 programs
overall. Novo was primarily focused on cardiovascular disease in the original
deal and on the hook for up to $2.7 billion in milestones.







The new deal expands the focus to cover Novo’s defining indications—obesity and
Type 2 diabetes—and increases the program cap to 20. If the programs hit their
milestones, Valo could receive $4.6 billion from Novo plus R&D funding and
potential royalty payments.















Novo’s broader strategy is to expand beyond diabetes and obesity, its core
areas, and into other diseases with a metabolic component. The original deal’s
focus on cardiovascular disease was a reflection of that strategy. Yet, while
Novo’s road map includes liver and kidney diseases, the expanded deal covers the
core therapeutic areas rather than branching out into other fields. 




RELATED

Novo Nordisk pays $60M for 3 preclinical assets as part of AI-powered cardio
collab with Valo

Novo decided to expand the deal after seeing the original collaboration identify
novel targets that could lead to differentiated cardiometabolic programs. The
partners are advancing multiple small molecules through drug discovery in
pursuit of the opportunities.







Landing a deal with Novo, a company that knows the platform better than most,
provides a boost for Valo at a tricky moment for the biotech. Valo reported the
failure of a phase 2 dia­bet­ic retinopa­thy trial at the end of last year. The
study represented an early clinical test of Valo’s plan to transform R&D using
AI, real-world patient data and human tissue modeling.






Novo Nordisk Valo Health Artificial Intelligence obesity drugs Type 2 diabetes
cardiovascular disease AI and Machine Learning Biotech Deals



RELATED CONTENT

Arch-backed Tenvie unveils with $200M and a neuro pipeline with assets from
Denali
Jan 8, 2025 08:00am
Sanofi inks $400M biobucks deal to test the mettle of Alloy’s antisense platform
Jan 8, 2025 05:08am
Galapagos splits in 2, laying off 40% of staff, shrinking pipeline and ending
Gilead partnership
Jan 8, 2025 04:49am
Cassava lays off 3rd of workforce in wake of phase 3 Alzheimer's fail
Jan 8, 2025 03:38am
See more articles
 * Connect
   
   * The Team
   * Advertise
   * Marketing Kit
   * Let's Talk
 * Join Us
   
   * Newsletters
   * Resources
   * RSS Feeds
 * Our Brands
   
   * Fierce Pharma
   * Fierce Biotech
   * Fierce Healthcare
 * Our Events
   
   * Life Sciences Events

©2025 Questex LLC All rights reserved.
Terms of use
Privacy Policy
Privacy Settings